Anteris Technologies Reports 63% Revenue Growth but Faces Increased Operating Losses in Q2 2026

Anteris Technologies Global Corp. reported its financial results for the second quarter of 2026, revealing a net sales increase of 63% to $1.0 million compared to $0.6 million in the same period last year. For the first half of 2026, net sales reached $1.5 million, up 28% from $1.2 million in the prior year. The growth in revenue was primarily attributed to increased sales of tissue products to 4C Medical Technologies, Inc. However, the company continues to face significant operating losses, with a net loss of $28.8 million for the quarter, a 37% increase from the $21.1 million loss reported in Q2 2025. For the six-month period, the loss was $51.7 million, up 20% from $43.0 million in the previous year.

The company's operating expenses also saw substantial increases, with research and development (R&D) expenses rising 43% to $23.4 million in Q2 2026, driven by costs associated with scaling manufacturing and activities related to the ongoing PARADIGM Trial. Selling, general, and administrative expenses increased by 68% to $8.4 million, reflecting higher employee costs and additional consulting expenditures. The total operating loss for the quarter was $31.0 million, compared to $20.9 million in the same quarter of 2025.

In terms of strategic developments, Anteris has made significant progress in its clinical programs, particularly with the DurAVR® Transcatheter Heart Valve (THV) System. The company has commenced patient recruitment for the PARADIGM Trial in both Europe and the United States, following FDA Investigational Device Exemption approval. Additionally, Anteris received full regulatory clearance from the French National Agency for Medicines and Health Products Safety, allowing for further expansion of the trial across Europe. The company is also focusing on enhancing its manufacturing capabilities to support the trial and future commercialization efforts.

Anteris has strengthened its financial position through capital raises, including a public offering that generated approximately $230 million and a private placement with Medtronic that brought in an additional $90 million. As of June 30, 2026, the company reported cash, cash equivalents, and restricted cash totaling $260.9 million, a significant increase from $12.6 million at the end of 2025. This capital is expected to support ongoing R&D and operational needs, although the company anticipates continued losses as it works towards regulatory approvals and product commercialization.

Looking ahead, Anteris Technologies remains focused on advancing its clinical programs and expanding its market presence. The company acknowledges the need for additional funding to support its long-term goals, including the completion of the PARADIGM Trial and the establishment of marketing and distribution capabilities. While the company has sufficient cash reserves to meet its operational requirements for at least the next 12 months, it recognizes the inherent uncertainties in achieving profitability and the potential challenges in securing future financing.